Also, higher bond yields Friday weighed on stocks.  Bond yields rose Friday after the US Jan unemployment rate unexpectedly fell to an 8-month low, and Jan average hourly earnings rose more than ...

Nike is dropping a new Air Max 1 Premium sneaker, and they're being referred to as the 'breakup sneaker.' Here's why and when ...

The sneaker features a full synthetic upper with synthetic overlays, an exposed carbon fiber plate, cable loop speed lacing, ...

Nike Air Max Dn8 features dual-pressured air units for better cushioning A global release in red is scheduled for March 6 on Nike’s site More men’s, women’s, and kids’ colorus are confirmed to launch ...

One reviewer says, "Absolutely love these trainers! The advice to size up half a size is bang on. Would definitely recommend them." Another reviewer says, "These are some comfortable sneakers to walk ...

If you're looking to have more eyes on you than Taylor Swift on Super Bowl Sunday, Nike has just the deal for you right now. ...

Nike is reportedly expanding its Air Max lineup with the upcoming Air Max Dn “Heat Map” sneakers. According to reports, the ...

Nike will reportedly bring back the beloved Air Zoom Spiridon OG “Metallic Silver” sneakers. The shoes are set to re-release ...

US stocks fell sharply on Friday as investors digested a mixed January employment report amid an escalation of concerns about a trade war following comments from Donald Trump.

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on January 31 and set a price target of $515.00. The company’s shares closed last ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential ...